Dalia Dawoud is the Scientific Adviser on the Science, Policy and Research Programme at The National Institute for Health and Care Excellence (NICE; London, UK).
Dawoud has a Doctor of Philosophy degree in Pharmaceutical Policy and Economics and a Master of Science in Economic Evaluation in Health Care. She is the current Chair of the International Society of Pharmacoeconomics and Outcomes Research’s Biosimilars Special Interest Group and has long experience in clinical guidelines development and health technology assessment, gained through working on NICE Clinical Guidelines as well as technology appraisals.
Dawoud’s research interests are focused on advanced methods of evidence synthesis and use in economic models, and the use of real-world evidence to inform drug development and health care decision making. Key research projects that Dawoud works on include the IMI GetReal Initiative and the EU’s Horizon 2020-funded Next Generation Health Technology Assessment (HTx) project.
Dawoud serves as Associate Editor for Pharmacoeconomics and Outcomes Research for Elsevier’s journal Research in Social and Administrative Pharmacy, and holds an adjunct position as Associate Professor at the Faculty of Pharmacy at Cairo University (Giza, Egypt).